Method of treating patients with dyspepsia syndrome combined with overweight
SUBSTANCE: invention refers to medicine, namely to gastroenterology, and can be used for providing the higher clinical effectiveness in the patients suffering dyspepsia syndrome combined with overweight. The method involves measuring an anxiety level (HARS) and a depression level (HDRS) according to Hamilton rating scales, assessing nutritional status by bioimpedancemetry, a degree of manifestation of sleep disorders, measuring glucose, testing glucose tolerance, immunoreactive insulin, cholesterol, high-density lipoprotein (HDLP), triglyceride in venous blood. If the patient is observed to suffer dyslipidemia and impaired glucose tolerance or variations of immunoreactive insulin, the preparation Dibikor is administered in a dose of 500 mg a day for three months. The patient suffering dyslipidemia and both of the disorders stated above requires administering Dibikor 1000 mg a day for three months. If the patient suffers an overweight with a body weight index falling within the range of 27 to 29.9 standard units and an active cell mass (ACM) percentage of 45 to 55 per cent as shown by bioimpedancemetry, the preparation Dietressa is administered in a dose of 1 tablet 3-4 times a day for three to six months. If the patient suffers an overweight with a body weight index falling within the range of 27 to 29.9 standard units and an active cell mass (ACM) percentage of 45 to 55 per cent as shown by bioimpedancemetry, the preparation Dietressa is administered in a dose of 2 tablet 3-4 times a day for three to six months. If the patient suffers mild and moderate sleep disorders and shows an emotive type of eating behaviour combined with mild affective disorders, the anti-depressant Valdoxane in a single dose of 25 mg a day for the night for two weeks. The course of the disease is followed by the anxiety and depression levels two weeks after the beginning of the therapy, with the positive progression of the diseases, the 25mg dose of Valdoxane remains unchanged to the end of the therapeutic course for three to six months. If no progression is exhibited, the dose is to be increased to 50 mg a day, and the therapy is continued from four to eight months. If the patient suffers severe sleep disorders and shows an emotive type of eating behaviour combined with moderate affective disorders, the anti-depressant Valdoxane in a single dose of 50 mg a day for the night for two to three months.
EFFECT: in each specific case, the method enables providing faster reduction of the clinical symptoms, including body fat weight reduction and active cell mass and water normalisation, normalising circadian rhythms of the vegetative balance, as well as prolonging the remission.
3 tbl, 2 ex
The invention relates to medicine, namely to a gastroenterologist, and can be used to improve the efficiency of treatment of patients with symptoms of dyspepsia in combination with excess body weight.
There is a method of treating syndrome dyspepsia, namely the appointment of antisecretory drugs - N2-blockers or proton pump inhibitors, as well as prokinetics: dopamine receptor antagonist - metoclopramide, domperidone and combined drug - itopride hydrochloride (Ivashkin V.T. et al., 2011 Recommendations DSA). Recommendations of the international consensus meeting "Maastricht-W" (2005) provide for eradication of infection Helicobacter pylori (HP) in patients with functional dyspepsia (Loginov A.F. Maastricht-3. Modern tactics diagnosis and treatment of Helicobacter pylori infection.// Farmateka. - 2006, №12. - P.46-48).
However, this therapy does not take into account the nutritional status, dietary intake, feeding behavior of the patient, does not influence the body mass index (BMI) in patients with combination syndrome dyspepsia (DM) and overweight.
It is known that nutrition has an impact on the development and course of the syndrome dyspepsia (ATL. Differential diagnosis of the syndrome dyspepsia.// "Consilium medicum", 2002. Volume 04, No. 9; Romanova M.M., Alexenko A.S. Comparative evaluation of pishevar the status and eating behavior in patients with the syndrome dyspepsia and in combination with obesity.// Issues of nutrition. 2011. No. 3. - P.76-77). It is also known that the presence of excess body weight is closely associated with disorders of actual power. It is established that in nutritional status and feeding behavior of these patients, there are significant deviations, and that the overweight have 30% of patients with symptoms of dyspepsia (Romanova M.M. Nutritional status and eating behaviors in patients with the syndrome dyspepsia and in combination with metabolic syndrome.// Russian journal of gastroenterology, Hepatology, Coloproctology - 2011, No. 5, volume XXI, Annex. - S). Also found that these patients have disorders of carbohydrate and lipid metabolism, affective disorders, sleep disorders (Romanova M.M., Babkin A.P. Features of affective disorders and circadian heart rate variability in patients with symptoms of dyspepsia in combination with obesity. // System analysis and control in biomedical systems. - 2007, Vol. 6, No. 2. - S. 462-466)that can serve as a predictor of organic pathology with the development of metabolic syndrome and requires correction.
Standard therapy of diabetes does not affect nutritional status, feeding behavior, diet, BMI, carbohydrate and lipid metabolism, daily chronobiology of heart rate variability (HRV), melatonin, the quality of life of patients. Meanwhile, being a powerful element of secondary prevention, the status is of the nutritional status and regulatory systems largely determine the effectiveness of therapy, the recurrence rate and prognosis and quality of life of patients.
The goal is to develop a method for the treatment of diabetes, allowing you to adjust the nutritional status, including carbohydrate and lipid metabolism, diet, circadian rhythms of autonomic balance, to accelerate the reduction of the clinical symptoms, prolong remission, improve the quality of life of patients by correcting circadian rhythm of secretion of melatonin.
The technical result is reached by the fact that patients DM conduct additional tests, the choice of impact, prescribe a comprehensive treatment.
Additional examination includes the following procedures. To assess anxiety and depressive disorders, conduct a survey on the following test questionnaires: the Hamilton depression rating scale to determine anxiety (HARS), the Hamilton depression rating scale to determine depression (HDRS). When interpreting the data take into account the total score for all questions, which determines the severity of the disorders: from 0 to 7.0 on a scale HARS and from 0 to 8.0 points on a scale HDRS - absence of symptoms of anxiety and depression; more of 7.0-16.0 scale HARS and more of 8.0 to 20.0 points on a scale HDRS - subclinical expressed signs of anxiety and depression; more 16.0 points on a scale HARS and more of 20.0 points on a scale HDRS - clinically expressed anxiety and depression.
To assess the nutritional status used the t bioimpedance, for example, using a hardware-software complex "Diamond" and assess the actual power with the help of a special assessment programs, for example using "Nutritent-1" (tutelian V.A. Metabolic crisis that is always with you.// Bulletin of the Association of distinguished physicians. - 2009, №1 (6). -P.18-21).
To assess the severity of sleep disorders, which is an indirect indicator of circadian rhythms in the secretion of melatonin, the questionnaire of quality of sleep (Insomnia: current diagnostic and therapeutic approaches/Ed. Aieline. M: Malpractice - M., 2005) and the scale of drowsiness Aporta (Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991; 14: 540-545).
To assess the type of eating behavior questionnaire DQIB (Wardle J. Eating stile: a validation study of the Dutch Eating Behaviour Questionnaire in normal subjects and women with eating disorders. J. Psychosom. Res. 1987; 31:161-169).
To assess the mode and circadian rhythm of food intake questionnaire used quality diet and circadian rhythm of food intake (Romanova M.M., Mukhortova I.S., Novels N.A. Objectification quality assessment regime and circadian rhythm nutrition // Scientific Herald of medicine Central black earth region - 2012, No. 46. - S-29).
To assess carbohydrate and lipid metabolism conduct blood tests for glucose, immunoreactive insulin, cholesterol, high density lipoprotein (HDL), and triglycerides.
Assessment of circadian secretion IU atonia conduct standard method enzyme immunoassay (http://drgtech.ru/elisa_pdf/Eia-1432_ru.pdf) reagents company Buhlmann for the study of metabolites of melatonin in the urine of the patient, collected during the day for four to six-hour intervals.
To assess quality of life using a questionnaire SF-36 (version 1).
When the mode is differentiated destination therapy, consider the following possible options:
if the patient has identified dyslipidemia and one of the disorders of carbohydrate tolerance or increased levels of immunoreactive insulin, prescribed medication Nik at a dose of 500 mg daily for three months;
if the patient has identified dyslipidemia and both disorders: carbohydrate tolerance and increased levels of immunoreactive insulin, prescribed medication Nik at a dose of 1000 mg per day for three months;
if the patient has excess body weight with a BMI in the range of 27 to 29.9 units, and according to bioimpedance the percentage of active cell mass (AMM) is from 45 to 55 percent, the prescribed drug distress at a dose of 1 tablet 3-4 times a day for three to six months;
if the patient has excess body weight with a BMI of 27 to 29.9 conventional units and AKM less than 45 percent or more than 55 percent, the prescribed drug distress at a dose of 2 tablets 3-4 times a day for three to six months,
if the patient has sleep disturbance light and medium severity, emotional type of eating behavior in combination the AI with affective disorders mild degree, then prescribe the antidepressant valdoxan 25 mg once a day at night for two weeks.
if the patient has sleep disorders high severity, emotional type of eating behavior in combination with affective disorders of moderate severity, prescribe antidepressant valdoxan 50 mg once at night for two to three months;
if the patient has sleep disturbances, emotional type of eating behavior in combination with affective disorders high severity, the patient is referred for treatment to a local psychiatrist.
Track the dynamics of the level of anxiety and depression two weeks after the start of treatment. If the dynamics is positive, then the dose of valdoxan 25 mg save until the end of therapy for three to six months, if the speaker is absent, then increase the dose to 50 mg per day and continue treatment for four to eight months.
While all patients prescribed an individual diet therapy is tailored to the nutritional status of the patient according to bioimpedance and evaluation of actual power. Teach classes with a psychotherapist with the participation of the nutritionist for the correction of eating disorders (Romanova M.M., Mukhortova I.S. Complex diagnostic and therapeutic procedures to the patient is in with gastroduodenal diseases associated with metabolic syndrome // Innovative technologies based on fundamental research: proceedings of the regional scientific-practical conference of students, graduate students and young scientists. - Voronezh: Voronezh state University, 2011. - S-124; Romanova M.M., Alexenko A.S. Features optimize the organization of schools health Center health // nutrition. 2011. No. 3. - P.35-37).
The method was tested in 12 patients. In the control group of 12 patients, the treatment was performed using standard therapy syndrome dyspepsia (Table 1, PL. 2, Table 3).
The application of this method allows you to accelerate the relief of clinical symptoms, lower BMI, fat mass, to normalize the content of the active cell mass (AKM) and water in the body, normalize circadian rhythms of autonomic balance, secretion of melatonin, meal, diet, nutritional behavior, lipid and carbohydrate metabolism, affective disorders, to prolong the period of remission.
|Correction of the results of actual food, eating behaviors and nutritional status six months after the start of treatment|
|Index (in % to the individual normal)||The known method||The proposed method|
|The residual increase in BMI||100||8,3|
|Residual reduction AKM||100||8,3|
|The residual increase in adipose tissue||100||8,3|
|The residual increase in the total water||100||8,3|
|Eating disorders||of 83.4||8,3|
|Violations actual power||75||8,3|
|Disturbances of circadian rhythm of food intake||of 83.4||-|
|Correction of the results of clinical manifestations, carbohydrate and lipid metabolism, waste rhythm of autonomic balance, melatonin six months after the start of treatment|
|Rate (% of patients with correction)||The known method||The proposed method|
|Disorders of glucose tolerance||-||91,7|
|The lack of affective disorders||16,6||91,7|
|The restoration of the circadian rhythm of HRV||-||100|
|The restoration of the circadian rhythm of secretion of melatonin||-||100|
|The relief of clinical symptoms||59,3||100|
|Positive dynamics of quality of life||16,6||100|
|Relapse within six months||of 83.4||-|
|Circadian rhythm of excretion of melatonin in patients with the syndrome of dispas is in the treatment of this method|
|The time interval h||The proposed method, before treatment, ng/ml||The proposed method, after treatment, ng/ml|
Example 1. Patient Z., 29 years old, came to the clinic at the place of residence to the gastroenterologist complaining of discomfort in the epigastric area, occurring after a meal, on excess weight.
Survey data: endoscopy revealed no pathology; ultrasound revealed no pathology; body mass index (BMI) is 28.7 conventional units. Identified sleep disorders, eating behaviors, nutritional status, dietary circadian rhythm of food intake, autonomic balance, secretion of melatonin mood disorders.
Diagnosis: syndrome dyspepsia with overweight.
The patient assigned to the standard treatment of the syndrome dyspepsia - drug ganaton 1 tablet before meals for 2 months.
Survey data after cured is I through 6 months: body mass index (BMI) is 29,1 conventional units - an increase of 0.4 from the original.
Persists sleep disorders, eating behaviors, nutritional status and dietary.
The survey revealed that 2 months after the end of treatment gonfanon discomfort in the epigastric region after eating reappeared, and periodically repeated.
Complaints about excessive weight are still present, the patient is dissatisfied with the results of treatment.
Example 2. Patient L., 31, went to the health Center clinics domiciliary with complaints of pain in the epigastric area, occurring after a meal, on excess weight.
These standard tests: endoscopy revealed no pathology, ultrasound revealed no pathology.
When choosing a differentiated destination therapy was taken into account that patient as a result of additional survey revealed: the body mass index (BMI) is 28,8 conventional units (in the range of 27 to 29.9 conventional units); the percentage of active cell mass of 42 percent (less than 45 percent); sleep disturbance moderate severity, emotional type of eating behavior in combination with affective disorders of moderate severity.
Diagnosis: syndrome dyspepsia with overweight. Affective disorder of moderate severity.
The patient is assigned the following cured the e: antidepressant valdoxan 50 mg once at night for three months, drug detressa 2 tablets 3-4 times a day for three months, as well as individual nutrition therapy tailored to the nutritional status of the patient according to bioimpedance and evaluation of actual meals, sessions with a psychotherapist with the participation of the nutritionist for the correction of eating disorders.
Survey data after treatment 6 months: body mass index (BMI) is 24.7 conventional units - a decrease of 4.2 from source.
Clinical manifestations of the syndrome dyspepsia, disorders of sleep, eating behaviors, nutritional status and dietary affective disorders, dyslipidemia, impaired glucose tolerance, increase the level of immunoreactive insulin was not detected.
The patient felt well satisfied with the success of treatment is positive.
Method for the treatment of patients with symptoms of dyspepsia in combination with excess body weight, including determination of the level of anxiety (HARS) and depression (HDRS) on scales of Hamilton, assessment of nutritional status using bioimpedance, the severity of sleep disturbance, assessment of the type of eating behavior, the glucose level estimation, test of tolerance to glucose, immunoreactive insulin, cholesterol, high density lipoprotein (HDL), triglycerides in venous blood, wherein when the mode is differe the sale destination therapy, consider the following possible options:
if the patient has identified dyslipidemia and impaired glucose tolerance or increased levels of immunoreactive insulin, prescribed medication Nik at a dose of 500 mg daily for three months; if the patient has identified dyslipidemia and impaired glucose tolerance in combination with increased levels of immunoreactive insulin, prescribed medication Nik at a dose of 1000 mg per day for three months; if the patient has excess body weight with a BMI in the range of 27 to 29.9 units, and according to bioimpedance, the percentage of active cell mass (AMM) is from 45 to 55 percent, then prescribe the drug distress at a dose of 1 tablet 3-4 times a day for three to six months; if the patient has excess body weight with a BMI of 27 to 29.9 conventional units and AKM less than 45 percent or more than 55 percent, the prescribed drug distress at a dose of 2 tablets 3-4 times a day for three to six months; if the patient has sleep disturbance light and medium severity, emotional type of eating behavior in combination with a mood disorder of mild degree, prescribe antidepressant valdoxan 25 mg once a day at night within two weeks; monitor the dynamics of the level of anxiety and depression two weeks after the start of treatment, if dyn is ka positive, the dose valdoxan 25 mg save until the end of therapy for three to six months, if the speaker is absent, then increase the dose to 50 mg per day and continue treatment for four to eight months; if the patient has sleep disorders high severity, emotional type of eating behavior in combination with affective disorders of moderate severity, prescribe antidepressant valdoxan 50 mg once at night for two to three months.
SUBSTANCE: invention refers to medicine and concerns diagnosis of an acute toxic hepatic injury in rats. The method consists in lipid recovery, namely in adding 25 mcg of 10% tezit with agitating the mixture by means of a shaker at 20°C and a vibration frequency of 120 a minute for 30 minutes and measuring total phospholipids and triglycerides in the solution. If their relation is 1.01-1.19; the blood alanine aminotransferase growth is increased to 0.50-0.62 mmole/l and more, the acute toxic hepatic injury in rats in diagnosed.
EFFECT: using the technique enables higher effectiveness and accuracy of diagnosing the acute toxic hepatic injury in rats.
SUBSTANCE: fasting blood test and blood test following taking amino acid mixture are conducted. First, fasting circulating blood volume, hematocrit and total calculated blood amino acid nitrogen content are determined in the morning. That is followed by oral administration of amino acid solution 100.0 ml transported according to one of absorption options with the known concentration of the solution and the amino acid nitrogen content therein The circulating blood volume, the hematocrit and the total calculated amino acid nitrogen content are determined again 30, 40, 50, 60, and 70 minutes after the administration of the amino acid sequence. The blood samples are measured for an amino acid absorption ratio by formula:
EFFECT: method enables measuring the total amino acid absorption rate in the digestive tract taking into account the transport system characteristics.
SUBSTANCE: antibacterial, infusion, syndromic, immunosupportive therapies and surgical management are conducted taking into account infant's severity and a process stage. The presence of an intrauterine infection is additionally detected. The presence and manifestation of purulent-septic values are determined. including procalcitonin, C-reactive protein, Calph-Caliph leucocytic intoxication index and immunoglobulin A. If observing at least one intrauterine infection and an increase of purulent-septic values in more than 1.5 times than a norm, a lymphotropic therapy is prescribed once a day for 7-10 days in the form of a single subcutaneous injection of a broad-spectrum antibacterial preparation into a right inguinal region 1 cm above an inguinal ligament, and two intravenous introductions of the other antibiotic.
EFFECT: invention enables reducing drug load on the patients, reducing risk of developing complications and neonatal and infant death.
1 tbl, 1 ex
SUBSTANCE: method involves controlling the patient's state, wherein the blood troponin I concentration is measured initially and every 60 minutes after the beginning of thrombolysis up to 4 hours, and if observing the troponin I concentration in 10 times and more as compared to the previous value, the thrombolytic therapy is considered to be effective. The invention can be used in acute cardiology for assessing the efficacy of the thrombolytic therapy in the patients with acute myocardial infarction with ST-segment elevation and enables assessing the efficacy of the thrombolytic therapy over a short period of time and to high precision. Recurrent infarctions in past medical history, intervention cardiac procedures and cardiac surgeries have no effect on the findings.
EFFECT: higher assessment accuracy.
3 dwg, 2 tbl, 3 ex
SUBSTANCE: invention represents method for prediction of threshold retinopathy of prematurity in infants having no ophthalmic signs of the disease characterised by the fact that blood serum is analysed for vascular endothelial growth factor (VEGF) up to the 33rd week of gestation; if the VEGF level is 1300 pg/ml or more, developing threshold retinopathy of prematurity is predicted.
EFFECT: enabling correction of therapeutic approach to premature newborns at the stages of nursing.
2 dwg, 1 tbl, 5 ex
SUBSTANCE: invention represents a diagnostic technique for external genital endometriosis involving blood serum analysis, differing by the fact that the blood serum is analysed for high-density lipoproteins, and if the derived value is 0.77 mmole/l and higher, external genital endometriosis is diagnosed.
EFFECT: invention enables providing higher accuracy and simplifying a diagnostic procedure for external genital endometriosis.
SUBSTANCE: general and biochemical blood values, coagulation profile, body weight, abdominal circumference (AC) by formula for I, II, III trimester of pregnancy; an appropriate biological age is determined by formula for I, II, III trimester of pregnancy. The appropriate biological age is subtracted from the biological age, and if the derived difference is -15.00 to -5.00 years, a delayed ageing is stated; the difference falling within the range of -4.99 to +4.99 years shows a physiological ageing, while an accelerated ageing is shown by the difference of +5.00 to +15.00 years.
EFFECT: using the declared method enables determining the biological age of a pregnant woman accurately.
SUBSTANCE: invention refers to medicine. A method for prediction of a risk of fractures consists in DNA recovery from peripheral venous blood leukocytes, by polymerase chain reaction with fluorescent detection, 3 polymorphic variants -1997G>T (g.3011T>G, rs1107946), -1663IndelT (g.3344_3345delTT, rs2412298) and +1245G>T (c.104-441G>T (rs1800012) found in a regulatory site of COLIA1 gene are genotyped. If having a combination of genotypes identified: 1997∗G∗T/-1663∗I∗D/ +1245∗G∗T, a category of individuals with a high risk of fractures is predicted.
EFFECT: using the declared method enables deriving criteria for evaluation of a risk of fractures with high prognostic significance.
1 tbl, 3 ex
SUBSTANCE: group of inventions relates to biotechnology and a method of producing proteins that are released during lysis of Vero cells, the method comprising the following steps: culturing and collecting Vero cells; break-down and lysis of Vero cells; purifying proteins released during lysis of Vero cells by hydrophobic chromatography on phenylsepharose 6FF, exclusive chromatography on sepharose, elution and concentration; the released proteins are a mixture of proteins with molecular weight of 11 kDa, 17-34 kDa, 55 kDa and 72-170 kDa. The proteins released during lysis of Vero cell according to the present invention have a wide range of applications. Said proteins can be used to control and analyse quality when producing vaccines using Vero cells with high sensitivity and good reproducibility. The present invention also provides a kit for analysing Vero cell HCP, characterised by high specificity, high sensitivity and good reproducibility.
EFFECT: kit can be used to control and analyse quality when producing not only non-secreted viral vaccines against viruses such as the hepatitis A virus, but other vaccines obtained using Vero cells as well.
18 cl, 14 tbl, 14 ex, 6 dwg
SUBSTANCE: invention aims at individual prediction of the therapeutic efficacy of chronic hepatitis C with pegylated interferon-alpha and ribavirin. The stages of the hepatic fibrosis from F0 to F4, the thrombocyte count, genotypes of the polymorphous rs12979860 locus of IL28B gene, anti-VHC IgM level, the presence of anti-NS5a IgG and the relation of anti-NS4ab IgG to anti-NS3 IgG titres are valued; thereafter the derived values are scored. The total score is derived, and if the total score of a prediction criterion is within the range of +9 to +6, a high probability of achieving a sustained virological response (SVR) is stated. The value falling within the range of +5 to +2, a good probability of achieving the SVR is stated, however a recurrence is considered to be possible. If the value exceeds +1, a moderate possibility of the SVR is considered with a very possible recurrence. The value from 0 to -9 is not to be associated with achieving the SVR.
EFFECT: method enables effective selecting patients for a standard dual antiviral therapy of chronic hepatitis C with underlying new therapeutic regimens.
3 tbl, 10 ex
FIELD: veterinary medicine.
SUBSTANCE: agent or stimulation of metabolic processes, prevention and treatment of gastrointestinal diseases in calves in early postnatal period comprises succinic acid as the energy stimulant, beet molasses as carbohydrate component, methionine as the stimulant of the digestive system, iodinol as the anti-infective component, and water in the following ratio of components, based on 0.5 litre: succinic acid 5.0 g; beet molasses 150.0 ml; methionine 2.0 g; iodinol 30-50 ml; water - the rest.
EFFECT: improvement of agent efficiency.
5 tbl, 2 ex
SUBSTANCE: invention refers to medicine, particularly to paediatrics and neonatology, and can be used for treating small premature infants at the hospital stage of developmental care. A therapeutic complex comprises administering a probiotic preparation into the newborns. The preparation is presented with a liquid probiotic containing E.faecium L3 109 CFU in 1 ml. If the enteral nutrition volume of the newborn is 5 ml or more, this preparation is orally administered in a dose of 0.5 ml 3 times a day for 14 days.
EFFECT: method is effective in children with a very low body weight, promotes normalising the intestinal microflora and reducing a rate of manifestations of infectious complications.
2 ex, 3 dwg, 3 tbl
SUBSTANCE: invention provides crystalline solid form of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalin-2-ylamino)-2-cyclohexylmethyl-butyric acid or crystalline hydrochloride of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalin-2-ylamino)-2-cyclohexylmethyl-butyric acid. Invention relates to pharmaceutical composition, possessing antagonistic activity with respect to mu-opioid receptor, which contains therapeutically effective quality of crystalline solid form.
EFFECT: invention provides methods of applying claimed crystalline solid forms in treatment of diseases associated with activity of mu-opioid receptors and methods of obtaining claimed crystalline solid forms.
27 cl, 9 dwg, 17 ex
SUBSTANCE: invention refers to veterinary science. A preparation for the prevention of diarrhoeas in newborn calves containing acid hydrolysate of animal blood, lactic, benzoic, succinic acids, additionally contains acetic acid, in the following ratio, wt %: acetic acid 0.4-0.5, lactic acid 0.05-0.06, benzoic acid 0.04-0.05, succinic acid 0.02-0.03, acid hydrolysate of animal blood - the rest.
EFFECT: invention provides a lower probability of diarrhoeas in the newborn calves and reducing a mortality rate.
3 tbl, 6 ex
SUBSTANCE: invention refers to medicine and may be used for relieving abdominal murmur. That is ensured by the oral administration of the bacteria Bifidobacterium animalis in dose 1×109 CFU a day. The bacteria are administered every day, for at least 15 days.
EFFECT: method provides relieving abdominal murmur in a healthy individual that is ensured by the developed dose schedule and specific rate of administration of the above prebiotic.
10 cl, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutics, namely to a composition for preventing and/or treating respiratory pathologies and/or infections and for improving intestinal functions. Using a symbiotic composition for preparing a drug preparation for preventing and/or treating the respiratory pathologies and/or infections. The symbiotic composition containing an active ingredient presented by a) a mixture containing the following bacterial strains: Lactobacillus plantarum LMG P-21020; Lactobacillus plantarum LMG P-21021; Lactobacillus rhamnosus DSM 16605; Lactobacillus rhamnosus DSM 19739; Bifidobacterium lactis LMG P-21384 and b) a prebiotic ingredient containing at least one scFOS (short-chain fructooligosaccharide) or GOS (galactooligosaccharide).
EFFECT: using the declared method enables more effectively preventing and/or treating the respiratory pathologies with simultaneously improving and/or controlling the intestinal functions.
11 cl, 2 tbl, 2 ex
SUBSTANCE: invention refers to medicine, particularly gastroenterology, and may be applied in treating secondary lactase deficiency. For this purpose, with underlying diet and drug-induced therapy, bifiform 1 tablet 2-3 times a day and No-spa 1-2 tablets 3 times a day are additionally administered. The therapeutic course makes 14 days.
EFFECT: method enables higher clinical effectiveness in secondary lactase deficiency.
SUBSTANCE: invention provides using a prepared compound of a ghrelin splicing version for preparing an effective drug preparation activating body weight and food intake gain and/or stimulating growth hormone release, as well as for treating or preventing cachexia, lipodystrophy and muscle atrophy.
EFFECT: higher clinical effectiveness.
6 cl, 6 dwg, 13 ex
SUBSTANCE: what is presented is the use of the strain Lactobacillus johnsonii in preparing a probiotic composition for prevention of postoperative abdominal and pelvic infections caused by pelvic liquid accumulation, anastomosis leakage, or caused by bacterial translocation.
EFFECT: colonic L Johnsonii Lai colonisation in the patients underwent colectomy for colorectal adenocarcinoma.
11 cl, 1 dwg, 1 tbl, 2 ex
SUBSTANCE: there are offered: application of a water-soluble indigestible saccharide for preparing a composition wherein the composition is introduced in a pregnant woman for improving the developing intestinal microflora of an expected newborn; reinforcing the immune system and/or preventing the diseases associated with the immune system of the expected newborn; or reinforcing the immune system of the foetus (versions). What is also presented is the application of the water-soluble indigestible saccharide wherein the saccharide is a galactose-containing saccharide containing at least 50% of galactose units of the total amount of monosaccharide units found in the saccharide for preparing the composition for reinforcing the immune system of the pregnant woman; improving the vaginal flora of the pregnant woman wherein the composition is introduced in the pregnant woman.
EFFECT: increased percentage of bifidus bacteria and lactic acid bacilli in the intestinal flora of pregnant women, intestinal colonisation of the newborn by lactic acid bacilli and reinforcement of the immune system.
11 cl, 2 ex
SUBSTANCE: developed agent contains trophoblastic β-1-glycoprotein (TBG), immunoglobulin (Ig) and additionally contains tetrapeptide H-Tyr-X-Y-Glu-OH, wherein X - Gln and/or Glu, Y - Cys (acm) and/or Cys.
EFFECT: effective treatment of autoimmune diseases by single doses containing TBG 1 mg, Ig 19 mg and tetrapeptide 20 mg.
6 tbl, 13 ex